Eugene, Efficacy Confirmed in Phase 1 Clinical Trial of Shingles Prevention Vaccine in Australia
[Asia Economy Reporter Minwoo Lee] IGEN announced on the 14th that it observed safety and efficacy after completing Phase 1 clinical trials of the shingles prevention vaccine 'EG-HZ' in Australia.
The trial involved a total of 40 healthy adults divided into five groups: one group receiving the active comparator GlaxoSmithKline (GSK)'s 'Shingrix' alone, and four groups receiving different formulations of 'EG-HZ'. After double-blinding both researchers and subjects, 'EG-HZ' and Shingrix were administered intramuscularly twice at two-month intervals. Observations were made at 60 days after the first vaccination, 90 days (30 days after the second vaccination), and 240 days, comparing the control group (Shingrix alone) with the test groups.
Hot Picks Today
"Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Even With a 90 Million Won Salary and Bonuses, It Doesn’t Feel Like Much"... A Latecomer Rookie Who Beat 70 to 1 Odds [Scientists Are Disappearing] ③
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
- "Am I Really in the Top 30%?" and "Worried About My Girlfriend in the Bottom 70%"... Buzz Over High Oil Price Relief Fund
- "It Has Now Crossed Borders": No Vaccine or Treatment as Bundibugyo Ebola Variant Spreads [Reading Science]
IGEN stated, "Through this clinical trial, we confirmed efficacy comparable to GSK's Shingrix as well as the safety and tolerability of EG-HZ." They added, "We plan to initiate licensing negotiations with overseas companies starting in the second half of this year and also intend to apply for Phase 2 clinical trials domestically."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
